Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Motilal Oswal Securities Ltd.
$46.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Lupin Ltd receives FDA approval for Generic trizivir tablets 


Tuesday, 10 Dec 2013 12:08am EST 

Lupin Ltd:Says received final approval for its Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base)/ 150 mg / 300 mg from the United States Food and Drugs Administration (FDA) to market a generic version of ViiV Healthcare’s (ViiV)Trizivir Tablets, 300 mg (base) / 150 mg / 300mg. 

Company Quote

1390.85
1.95 +0.14%
23 Oct 2014